NCT06297629View on ClinicalTrials.gov

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 1, 2024

Primary Completion Date

July 11, 2024

Study Completion Date

July 11, 2024

Conditions
Allogeneic Stem Cell Transplantation
Interventions
DRUG

ASTX727

Given by PO

DRUG

Donor Lymphocyte Infusion

Given by Infusion

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER